CYTKCytokinetics, Incorporated

Cytokinetics, Incorporated is a specialty cardiovascular biopharmaceutical company focused on discovering, developing, and commercializing medicines that target muscle biology. Its current work centers on therapies for cardiac muscle dysfunction, particularly heart conditions in which the heart’s contractile performance is compromised. The company markets MYQORZO, an oral cardiac myosin inhibitor for symptomatic obstructive hypertrophic cardiomyopathy, and is advancing additional drug candidates such as aficamten for broader hypertrophic cardiomyopathy use and omecamtiv mecarbil for heart failure. Cytokinetics also develops other muscle-directed candidates in clinical-stage programs, reflecting its emphasis on precision treatments for diseases affecting cardiac and skeletal muscle function. Headquartered in South San Francisco, California, Cytokinetics plays a specialized role in the biopharmaceutical market by focusing on muscle performance disorders within cardiovascular medicine.